Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biogen and Denali’s pivotal trial of a first-in-class LRRK2 kinase inhibitor is a long-awaited test of a target that could provide a path to disease-modifying therapies for Parkinson disease.
MYC, one of the most commonly dysregulated proteins in cancer, has long seemed ‘undruggable’. Can a clinical-stage cell-penetrating peptide — or preclinical small-molecule inhibitors and degraders — prove otherwise?
Bristol Myers Squibb’s first-in-class TYK2 inhibitor and blockbuster contender deucravacitinib showcases the role for heavy hydrogen in novel drug discovery.
As a surge of cancer drugs with new synthetic lethality targets enter the clinic, the opportunities and challenges of the underlying discovery strategies are coming into focus.
A PARP1-selective drug and a pipeline of ATR inhibitors demonstrate the near-term opportunities and long-term challenges for synthetic lethality in anticancer drug development.
With the FDA’s approval of the first TCR-based bispecific T cell engager, an emerging biological modality aims to take on new targets for solid cancers.
BMS’s LAG3-targeted antibody relatlimab is poised to expand the checkpoint inhibitor class beyond PD1 and CTLA4, but questions remain about the target’s future.